Here we show lenabasum modulated the immune environment within 12 weeks via a decrease in CD4+ T cells and pathogenic cytokines in DM such as IFN-β, IFN-γ, and IL-31 within the skin. This evidence concerns the gene IFNB1 and dermatomyositis.